Short answer
STANDARD BIOTOOLS INC. (LAB) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Filing contains only the May 5, 2026 signature page, not substantive fiscal-year 2026 results.
STANDARD BIOTOOLS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Filing contains only the May 5, 2026 signature page, not substantive fiscal-year 2026 results
- No revenue, earnings, cash flow, guidance, or other operating figures available for investor analysis
Item 7.01 · Regulation FD Disclosure
- Reg FD disclosure incorporates the “Full Year 2026 Revenue Outlook” into the 8-K
- 2026 revenue guidance details appear in the referenced exhibit, not the filing section
- Forward-looking statement disclaimer applies to the outlook
- Standard BioTools company description also incorporated by reference
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $21.1M, up 5% YoY, with consumables up 35% to $11.0M offsetting instruments down 33% to $4.5M
- Operating loss narrowed 54% to $12.5M; adjusted EBITDA loss improved 78% to $3.1M through restructuring-driven cost reductions
- Cash and investments totaled $523.6M at quarter-end, plus a $25M earnout received after quarter-end, supporting acquisition capacity
- Continuing-operations net loss fell to $14.6M from $23.4M, while discontinued-operations income of $141.7M produced net income of $127.1M
- FY2026 revenue outlook maintained at $80M-$85M; management targets positive adjusted EBITDA exiting 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other STANDARD BIOTOOLS INC. 8-K filings
Get the next LAB 8-K as it lands
Follow LAB for push alerts, or ask the research agent what this filing means.